Vol 7, No 2 (2022)
Original article
Published online: 2022-06-30

open access

Page views 4845
Article views/downloads 1635
Get Citation

Connect on Social Media

Connect on Social Media

Cardiovascular risk assessment based on SCORE and SCORE2

Alicja Rzepka-Cholasinska1, Michał Kasprzak2, Piotr Michalski1, Łukasz Pietrzykowski1, Klaudyna Grzelakowska3, Aldona - Kubica1
Medical Research Journal 2022;7(2):164-169.

Abstract

Introduction: The 2021 European Society of Cardiology (ESC) guidelines on cardiovascular disease prevention introduced significant changes compared to the previous 2016 edition. Particular attention should be paid to the stepwise approach to treating patients with cardiovascular risk factors, based on individual risk stratification. The SCORE scale previously recommended for risk assessment and its Polish adaptation Pol-SCORE have been replaced by SCORE2 and SCORE2-OP in the latest guidelines.

The aim of the study: The aim of this study is a parallel cardiovascular risk assessment with Pol-SCORE and SCORE2 in the same patient population.

Material and methods: The study included 159 patients aged 40 to 70 years without prior cardiovascular events that were diagnosed with hypertension or hypercholesterolemia between 6 and 24 months before the start of the study. Patients with diabetes mellitus, chronic kidney disease, and familial hypercholesterolemia were excluded from the study.

Results: The 10-year risk of cardiovascular event (SCORE2) was twice as high as the risk of cardiovascular death (Pol-SCORE). In the Pol-SCORE scale, most patients were at moderate risk (65.41%), while based in the SCORE2 scale the dominant group was in the low-to-moderate risk category (49.06%). Among the patients with moderate risk of cardiovascular death (Pol-SCORE), low-to-moderate, high, and very high CVD risk groups (SCORE2) were reported. In other cases, the risk assessments of cardiovascular death and cardiovascular event appear to be consistent. This observation is confirmed by the strong positive correlation (R = 0.7493; p < 0.0001) between the Pol-SCORE and SCORE2 scales.

Conclusions: Cardiovascular risk assessments based on the SCORE and SCORE2 scales are broadly consistent, but in individual cases, the results fall into radically different risk categories.

Article available in PDF format

View PDF Download PDF file

References

  1. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004; 364(9438): 937–952.
  2. Khawaja FJ, Rihal CS, Lennon RJ, et al. Temporal trends (over 30 years), clinical characteristics, outcomes, and gender in patients ≤50 years of age having percutaneous coronary intervention. Am J Cardiol. 2011; 107(5): 668–674.
  3. Conroy RM, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11): 987–1003.
  4. Piepoli MF, Hoes AW, Agewall S, et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
  5. Zdrojewski T, Jankowski P, Bandosz P, et al. [A new version of cardiovascular risk assessment system and risk charts calibrated for Polish population]. Kardiol Pol. 2015; 73(10): 958–961.
  6. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  7. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25): 2439–2454.
  8. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42(25): 2455–2467.
  9. Kubica A, Pietrzykowski Ł. The therapeutic plan implementation in patients discharged from the hospital after myocardial infarction. Medical Research Journal. 2021; 6(2): 79–82.
  10. Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Medication adherence and its determinants in patients after myocardial infarction. Sci Rep. 2020; 10(1): 12028.
  11. Pietrzykowski Ł, Kasprzak M, Michalski P, et al. The influence of patient expectations on adherence to treatment regimen after myocardial infarction. Patient Educ Couns. 2022; 105(2): 426–431.
  12. Kubica A, Michalski P, Kasprzak M, et al. Two different approaches to assess adherence to medication in Polish cohort of the EUROASPIRE V registry. Medical Research Journal. 2022.
  13. Kubica A, Adamski P, Bączkowska A, et al. The rationale for Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) project is to support multicentre randomized clinical trial Evaluating Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA – SIRIO 2). Medical Research Journal. 2020; 5(4): 244–249.
  14. Michalski P, Kasprzak M, Siedlaczek M, et al. The impact of knowledge and effectiveness of educational intervention on readiness for hospital discharge and adherence to therapeutic recommendations in patients with acute coronary syndrome. Medical Research Journal. 2020.
  15. Jankowski P, Kosior DA, Sowa P, et al. Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiol J. 2020; 27(5): 533–540.
  16. Kubica A, Gruchała M, Jaguszewski M, et al. Adherence to treatment — a pivotal issue in long-term treatment of patients with cardiovascular diseases. An expert standpoint. Medical Research Journal. 2017; 2(4): 123–127.
  17. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
  18. Pietrzykowski Ł, Kasprzak M, Michalski P, et al. Therapy Discontinuation after Myocardial Infarction. J Clin Med. 2020; 9(12).
  19. Kubica A, Kosobucka A, Fabiszak T, et al. Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires? Curr Med Res Opin. 2019; 35(2): 341–349.
  20. Kosobucka A, Michalski P, Pietrzykowski Ł, et al. Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction. Patient Prefer Adherence. 2018; 12: 333–340.
  21. Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol. 2016; 74(1): 61–67.
  22. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
  23. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014; 742: 47–54.
  24. Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Knowledge about health and disease in obese patients after myocardial infarction. An observational study. Medical Research Journal. 2017; 2(4): 135–140.
  25. Kubica A, Kosobucka A, Michalski P, et al. Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases. Medical Research Journal. 2017; 2(4): 115–122.
  26. Michalski P, Kasprzak M, Pietrzykowski Ł, et al. Ambulatory assessment of medication adherence in high cardiovascular-risk patients. The Polish population of the EUROASPIRE V survey. Medical Research Journal. 2021; 6(4): 316–321.
  27. Laskowska E, Michalski P, Pietrzykowski Ł, et al. Implementation of therapeutic recommendations in high cardiovascular-risk patients. The Polish population of EUROASPIRE V survey. Medical Research Journal. 2021; 6(3): 230–236.
  28. Kosobucka A, Pietrzykowski Ł, Michalski P, et al. Impact of readiness for discharge from the hospital on the implementation of the therapeutic plan. Medical Research Journal. 2020; 5(4): 256–264.